Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €75.33 EUR
Change Today +2.49 / 3.42%
Volume 792.0
LLY On Other Exchanges
New York
SIX Swiss Ex
Sao Paulo
EN Paris
As of 11:58 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

eli lilly & co (LLY) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/23/15 - €82.61
52 Week Low
10/16/14 - €47.94
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ELI LILLY & CO (LLY)

eli lilly & co (LLY) Details

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of major depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products for the treatment of erectile dysfunction and benign prostatic hyperplasia, thrombotic cardiovascular events, and cardiac ischemic complications. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine, cattle, and poultry; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; chronic allergic dermatitis and kidney diseases in cats. It has collaboration agreement with ZP Opco, Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

39,135 Employees
Last Reported Date: 02/19/15
Founded in 1876

eli lilly & co (LLY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $1.0M
Executive Vice President of Science & Technol...
Total Annual Compensation: $1.0M
Senior Vice President and President of Lilly ...
Total Annual Compensation: $682.9K
General Counsel and Senior Vice President
Total Annual Compensation: $765.0K
Compensation as of Fiscal Year 2014.

eli lilly & co (LLY) Key Developments

Eli Lilly and Company Receives FDA Breakthrough Therapy Designation for Abemaciclib

Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. This designation is based on data from the breast cancer cohort expansion of the company's Phase I trial, JPBA, which studied the efficacy and safety of abemaciclib in women with advanced or metastatic breast cancer. Patients in this cohort had received a median of seven prior systemic treatments. According to the FDA, Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint.

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc. Announce Financial Commitment and Continued Scientific Partnership

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc. announced financial commitment and continued scientific partnership to support the recently established Imaging Dementia 'Evidence for Amyloid Scanning (IDEAS) Study'. The IDEAS Study will assess the clinical usefulness and value in using an amyloid brain positron emission tomography (PET) scan in certain situations when evaluating Alzheimer's disease (AD) and other dementias. Amyvid™ (Florbetapir F-18 Injection), Lilly's FDA-approved radioactive PET diagnostic agent for the estimation of beta-amyloid neuritic plaque density in the brain, will be one diagnostic agent available for use in the study. Manufactured in and distributed from 30 radiopharmacy facilities throughout the United States, Amyvid is currently supplied to a robust network of PET imaging sites by Siemens' PETNET Solutions and Cardinal Health. Amyvid for intravenous use is supplied in 10 mL, 30 mL, or 50 mL multidose vials containing 500-1900 MBq/mL Florbetapir F-18.

Zosano Dissolves Licensing Partnership with Eli Lilly for ZP-PTH

Zosano Pharma (US) has announced it will stop developing the daily version of its ZP-PTH candidate treatment for severe osteoporosis and instead resume development of the weekly version. The company said its decision was prompted by feedback from Japanese regulatory authorities that they would require additional studies that would be likely to delay commercialisation in Japan by about a year. Zosano's licensing partnership with Eli Lilly (US) for ZP-PTH has therefore been dissolved. Zosano has discontinued its development of daily ZP-PTH despite reportedly receiving positive feedback from the US FDA and it had been on course to initiate a Phase III programme in the United States. In light of the feedback from the Japanese authorities, however, Zosano believes its resources would be more prudently deployed by focusing on weekly ZP-PTH, for which it is planning to initiate a Phase II trial in the first half of 2016. Zosano had entered into its partnership with Lilly in late 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:GR €75.33 EUR +2.49

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $55.64 USD -0.40
Allergan plc $274.84 USD -1.32
Amgen Inc $149.59 USD -0.31
Bristol-Myers Squibb Co $61.44 USD +0.93
Medtronic PLC $72.60 USD +0.55
View Industry Companies

Industry Analysis


Industry Average

Valuation LLY Industry Range
Price/Earnings 43.5x
Price/Sales 4.5x
Price/Book 6.1x
Price/Cash Flow 45.1x
TEV/Sales 4.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at